(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...
May 17, 2012
0
0
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.
Apr 1, 2012
0
0
An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase ...
Mar 16, 2012
0
0
In a bid to make cancer immunotherapy more effective, researchers report they have succeeded in halting the progress of aggressive melanoma in its tracks - at least briefly - in seven patients treated with an army of cloned ...
Mar 6, 2012
0
0
Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it.
Mar 6, 2012
0
0
A small, early-phase clinical trial to test the effectiveness of treating patients with advanced melanoma using billions of clones of their own tumor-fighting cells combined with a specific type of chemotherapy has shown ...
Mar 5, 2012
0
0
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...
Mar 1, 2012
0
0
Swiss drug giant Roche said on Monday it had been given European Union approval for its treatment to fight a highly aggressive form of skin cancer.
Feb 20, 2012
0
0
(Medical Xpress) -- A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to ...
Jun 4, 2011
0
0
